Adamis Pharmaceuticals (NASDAQ:ADMP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. “

Other equities analysts have also recently issued research reports about the company. Maxim Group set a $14.00 target price on Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 5th. B. Riley set a $10.00 target price on Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, November 30th. Finally, ValuEngine cut Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Adamis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $10.33.

Shares of Adamis Pharmaceuticals (NASDAQ ADMP) traded down $0.02 during trading on Tuesday, hitting $4.43. The stock had a trading volume of 364,800 shares, compared to its average volume of 593,089. The stock has a market cap of $138.56, a PE ratio of -6.33 and a beta of 0.33. The company has a current ratio of 3.93, a quick ratio of 3.79 and a debt-to-equity ratio of 0.06. Adamis Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $6.45.

Several hedge funds have recently modified their holdings of the stock. Northern Trust Corp lifted its stake in shares of Adamis Pharmaceuticals by 5.5% during the 2nd quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock worth $266,000 after acquiring an additional 2,686 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its stake in shares of Adamis Pharmaceuticals by 22.2% during the 2nd quarter. Stonebridge Capital Advisors LLC now owns 27,500 shares of the specialty pharmaceutical company’s stock worth $143,000 after acquiring an additional 5,000 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Adamis Pharmaceuticals by 131.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 27,464 shares of the specialty pharmaceutical company’s stock worth $143,000 after acquiring an additional 15,577 shares during the last quarter. Virtu KCG Holdings LLC lifted its stake in shares of Adamis Pharmaceuticals by 103.2% during the 2nd quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock worth $200,000 after acquiring an additional 19,538 shares during the last quarter. Finally, First Allied Advisory Services Inc. bought a new stake in shares of Adamis Pharmaceuticals during the 2nd quarter worth approximately $114,000. 16.61% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/16/adamis-pharmaceuticals-admp-upgraded-by-zacks-investment-research-to-hold.html.

Adamis Pharmaceuticals Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.